US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.04 against a street estimate of -0.01 — a beat of 500.0%.
Analysts rate BioLife Solutions Inc a hold (1 buy, 8 hold, 0 sell out of 9) with an average price target of $31.29.
| Fund | Stake |
|---|---|
| T. Rowe Price Investment Management,Inc. | 13.80% |
| BlackRock Inc | 13.03% |
| Casdin Capital, LLC | 9.51% |
| Amvescap Plc. | 4.58% |
| Vanguard Capital Management, LLC | 4.01% |
| State Street Corp | 3.38% |
| Geode Capital Management, LLC | 2.22% |
| Massachusetts Financial Services Company | 2.21% |
| Document | Date |
|---|---|
| Acquisition completed · Q4 2026 HEADLINE NUMBERS • Repligen Corporation completed its acquisition of BioLife Solutions on October 6, 2026. • BioLife shareholders received $11.25 in | 2026-10-06 |
| Company announcement · Q3 2026 BIOLIFE SOLUTIONS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Merger consideration: $11.25 cash plus 0.1442 shares of Repligen common stock per BioL | 2026-09-09 |
| Quarterly report · Q2 2026 BIOLIFE SOLUTIONS, INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Revenue (6 months): $55,966,000 (up 23% from $45,492 | 2026-08-06 |
| Results announced · Q3 2026 BIOLIFE SOLUTIONS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q2 2026: $28.5 million, up 21% year-over-year from $23.4 million in Q2 2 | 2026-08-06 |
| Reg FD disclosure · Q3 2026 BIOLIFE SOLUTIONS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Merger Agreement Date: July 21, 2026 • Current Report Filing Date: August 3, 2026 • Ac | 2026-08-03 |
| Material agreement · Q3 2026 BIOLIFE SOLUTIONS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Merger deal value per BioLife share: $11.25 cash + 0.1442 shares of Repligen common st | 2026-07-22 |
| Reg FD disclosure · Q2 2026 BIOLIFE SOLUTIONS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No specific financial metrics disclosed in this filing • Document is a Form 8-K Curren | 2026-06-03 |
| Quarterly report · Q1 2026 BIOLIFE SOLUTIONS, INC. – Q1 2026 (10-Q) SUMMARY HEADLINE NUMBERS • Revenue: $27.5 million for Q1 2026, up 24.7% from $22.1 million in Q1 2025 • Net | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| BioLife merged with Repligen in a cash-and-stock transaction BioLife completed its merger with Repligen. Each BioLife share was converted into $11.25 in cash plus 0.1442 Repligen shares, with cash paid for any fractional Repligen share. Employee stock | 2026-10-06 |
| HSR antitrust waiting period expired for acquisition merger agreement Repligen Corporation is acquiring BioLife Solutions through a merger deal announced in July 2026. BioLife shareholders will receive $11.25 in cash plus 0.1442 Repligen shares per BioLife sha | 2026-09-09 |
| Agreement and plan of merger with Repligen Corporation announced BioLife Solutions is being acquired by Repligen Corporation in an all-cash merger deal announced on July 21, 2026. The transaction involves two sequential mergers that will make BioLife a wh | 2026-08-03 |
| Repligen acquires BioLife Solutions in merger agreement for cash and stock Repligen Corporation agreed to acquire BioLife Solutions for $11.25 cash plus 0.1442 shares of Repligen stock per BioLife share. Both companies' boards approved the deal. BioLife shareholder | 2026-07-22 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BioLife Solutions Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.